Pneumologie 2023; 77(S 01): S14
DOI: 10.1055/s-0043-1760897
Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: interim analysis of an rw pt registry in Germany
F Griesinger
1
Pius-Hospital Oldenburg; University Medicine Oldenburg; Hematology/Oncology, Internal Medicine-Oncology
,
S Popat
2
Department of Medicine, The Royal Marsden Hospital – NHS Foundation Trus
,
P Okhuoya
3
Astrazeneca
,
L Servidio
4
Global Medical Affairs Department, Astrazeneca US
,
M Fonseca
5
Iqvia, Porto Salvo
,
E Tolani
6
Iqvia
,
S Lu
7
Medical Oncology Department, Shanghai Chest Hospital, Shanghai Jiao Tong University
,
S Zacharias
8
Department of Data Management, Statistics and Medical Informatics, Iomedico
,
M Thomas
9
Thoraxklinik Heidelberg gGmbH, Universitätsklinikum Heidelberg
› Author Affiliations
